158461-54-2

Basic information

• Product Name: Benzenamine, 2-(3-pyridinyl)-5-(trifluoromethyl)-
• CAS NO: 158461-54-2
• Molecular Formula: C12H9F3N2
• Molecular Weight: 238.212
• Mol File: 158461-54-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzenamine, 2-(3-pyridinyl)-5-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 2-(3-pyridinyl)-5-(trifluoromethyl)-(158461-54-2)
• EPA Substance Registry System: Benzenamine, 2-(3-pyridinyl)-5-(trifluoromethyl)-(158461-54-2)

Safety Data

• Hazardous Substances Data: 158461-54-2(Hazardous Substances Data)

Upstream product

• 400-98-6 4-trifluoromethyl-2-nitroaniline 
• 110-86-1 pyridine 
• 454-79-5 2-Bromo-5-trifluoromethylaniline 
• 1692-25-7 3-pyridylboronic acid 
• 158461-31-5 3-(2-nitro-4-(trifluoromethyl)phenyl)pyridine 

Downstream Products

• 1296770-67-6 C₁₂H₇F₃N₄ 
• 1296770-89-2 CF₃O₃S^(1-)*C₁₃H₁₀F₃N₄⁽¹⁺⁾ 
• 158461-80-4 [1-Methyl-2-(2-pyridin-3-yl-5-trifluoromethyl-phenylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; Z is a monocyclic aryl or heteroaryl group, each of which is optionally substituted by one ormore substituents selected from alkyl, cycloalkyl, halo, alkoxy, CN, haloalkyl and OH; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, C land alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl,Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl andhaloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl,SO2NR12R13, heteroaryl, CONR10R11 and alkyl, wherein said heteroaryl group is optionallysubstituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R8 is selected from H, alkyl, haloalkyl and halo; and R9 is H, alkyl or halo; R10 and R11 are each independently H or alkyl; and R12 and R13 are each independently H or alkyl. Further aspects of the invention relate to such compounds for use in the field of immuno- oncology and related applications. Another aspect of the invention relates to compounds of formulae (la) and (lb).

Ruthenium-catalyzed γ-carbolinium ion formation from aryl azides; Synthesis of dimebolin

A range of γ-carbolines were produced stereoselectively from ruthenium(III)-catalyzed reactions of 3-pyridyl substituted aryl azides. Other catalysts and conditions were neither as selective nor as high-yielding. This method was used to synthesize dimebolin in a concise and efficient manner.

Synthesis and antiarrhythmic activity of disubstituted phenylpyridine derivative

A series of disubstituted phenylpyridine derivatives was synthesized and their antiarrhythmic effects against chloroform-induced ventricular arrhythmias in mice were examined. Among them, 2- and 3-[2-(3- aminobutyramido)-4-(2,2,2-trifluoroethoxy)phenyl]pyridines (23h, 24h) and 3- [2-(3-aminobutyramido)-4-ethoxyphenyl]pyridine (24i) showed potent antiarrhythmic activity. They had approximately twice the potency of mexiletine (III). Compound 24i was selected from this series as a candidate for further development; it was found to have a class I B electrophysiological character and to show a slow kinetic rate-dependent block (RDB) of the sodium channel in cardiac muscle.